Isosorbide
drugOn this page
Also known as AT-101IsmoticIsobideIsosorbidaNSC-40725SID29218045SID29216190SID29218044SID170465187
Summary
Isosorbide (CHEMBL1200660) is an approved small molecule; indicated across 12 conditions including b-cell chronic lymphocytic leukemia and head and neck squamous cell carcinoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 12 conditions
- Clinical trials: 16
- Chemistry: 146.14 Da · C6H10O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200660 |
| Name | Isosorbide |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 12597 |
| Molecular formula | C6H10O4 |
| Molecular weight | 146.14 |
| InChIKey | KLDXJTOLSGUMSJ-JGWLITMVSA-N |
SMILES: C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O)O
IUPAC name: (3S,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol
Also known as: AT-101, Ismotic, Isobide, Isosorbida, Isosorbide, NSC-40725, SID29218045, ISOSORBIDE, SID29216190, SID29218044, isosorbide, SID170465187
Patent coverage: 11,882 distinct patent families (35,343 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Ferritin light chain, Thyroid hormone receptor beta.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| THRB | 7.4 | Potency | 39.8 | nM | CHEMBL_ACT_4015794 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
12 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| B-cell chronic lymphocytic leukemia | 2 | MONDO:0004948 | EFO:0000095 |
| head and neck squamous cell carcinoma | 2 | MONDO:0010150 | EFO:0000181 |
| diffuse large B-cell lymphoma | 2 | MONDO:0018905 | EFO:0000403 |
| hypertensive disorder | 2 | MONDO:0005044 | EFO:0000537 |
| prostate adenocarcinoma | 2 | MONDO:0005082 | EFO:0000673 |
| mantle cell lymphoma | 2 | MONDO:0018876 | EFO:1001469 |
| laryngeal neoplasm | 2 | MONDO:0021071 | MONDO:0002358 |
| follicular lymphoma | 2 | MONDO:0018906 | MONDO:0018906 |
| small cell lung carcinoma | 1 | MONDO:0008433 | EFO:0000702 |
| neoplasm | 1 | MONDO:0005070 | MONDO:0004992 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 16.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| PHASE1/PHASE2 | 4 |
| Not specified | 3 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02718846 | PHASE4 | COMPLETED | Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets |
| NCT06765993 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere’s Disease |
| NCT00275431 | PHASE2 | COMPLETED | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies |
| NCT00286780 | PHASE2 | COMPLETED | Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia |
| NCT00286793 | PHASE1/PHASE2 | COMPLETED | Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC |
| NCT00286806 | PHASE1/PHASE2 | COMPLETED | A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer |
| NCT00397293 | PHASE1/PHASE2 | COMPLETED | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer |
| NCT00440388 | PHASE2 | COMPLETED | Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin’s Lymphoma |
| NCT00544960 | PHASE2 | COMPLETED | A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer |
| NCT00561197 | PHASE1/PHASE2 | TERMINATED | An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer |
| NCT00666666 | PHASE2 | COMPLETED | R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer |
| NCT01285635 | PHASE2 | TERMINATED | A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck |
| NCT01633541 | PHASE2 | COMPLETED | Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer |
| NCT00685945 | Not specified | COMPLETED | Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3 |
| NCT00766805 | Not specified | COMPLETED | Endoscopic Variceal Ligation (EVL)+ Drugs Versus Endoscopic Variceal Ligation (EVL) Alone For Secondary Prophylaxis |
| NCT02258620 | Not specified | COMPLETED | Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.